Budget Amount *help |
¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2010: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2009: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2008: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
|
Research Abstract |
Defect of vesicle transport related molecule Hrs diminishes the expression of c-Myc. There are some reports concerning the relationship between c-Myc overexpression and poor prognosis of cancer patients. We attempted to identify new therapeutic target utilizing c-Myc overexpression as a biomarker. We used a siRNA library consists of 3500 druggable genome for a screening, and selected Casein Kinase 1 epsilon as a new target. We also showed IC261, a specific inhibitor of Casein Kinase 1 epsilon has therapeutic effects in mouse ovarian cancer model.
|